New triple therapy aims to stop liver cancer from coming back
NCT ID NCT07618546
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving a combination of chemotherapy directly into the liver (HAIC) plus two drugs (camrelizumab and apatinib) before and after surgery can prevent liver cancer from returning in high-risk patients. About 208 people with resectable liver cancer and high-risk features will be randomly assigned to either the triple therapy plus surgery or surgery alone. The main goal is to see if the combo improves how long patients live without their cancer coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camrelizumab, apatinib mesylate, and FOLFOX-HAIC (oxaliplatin, leucovorin, 5-fluorouracil)
What this could lead to
If successful, this combination could lower the chance of liver cancer returning after surgery, improving long-term survival for high-risk patients.
What could go wrong
This is an early-stage trial with only 208 participants, so results may not apply to everyone. The drugs can cause serious side effects like immune reactions or liver damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.